(Q52940754)

English

Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen.

scientific article published on 12 January 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

0 references

rhinoconjunctivitis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Rolinck-Werninghaus C

1

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Kopp M

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Liebke C

3

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Lange J

4

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Wahn U

5

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Niggemann B

6

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

publication date

12 January 2005

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

International Archives of Allergy and Immunology

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

136

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

2

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

134-141

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children monosensitized to mites

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

The effect of immunotherapy on bronchial hyperresponsiveness and eosinophil cationic protein in pollen-allergic patients

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardized in mass units in patients with rhinoconjunctivitis, asthma, or both.

1 reference

https://api.crossref.org/works/10.1159%2F000083320

21 January 2018

Identifiers

10.1159/000083320

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 May 2018

http://europepmc.org/abstract/MED/15650310

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52940754&oldid=1242825793"